1.Ustusolate E and 11α-Hydroxy-Ustusolate E induce apoptosis in cancer cell lines by regulating the PI3K/AKT/mTOR and p-53 pathways.
Mewlude REHMUTULLA ; Sitian ZHANG ; Jie YIN ; Jianzheng HUANG ; Yang XIAO ; Zhengxi HU ; Qingyi TONG ; Yonghui ZHANG
Chinese Journal of Natural Medicines (English Ed.) 2025;23(3):346-353
Cancer represents a significant disease that profoundly impacts human health and longevity. Projections indicate a 47% increase in the global cancer burden by 2040 compared to 2020, accompanied by a further rise in the associated economic burden. Consequently, there is an urgent need to discover and develop new alternative drugs to mitigate the global impact of cancer. Natural products (NPs) play a crucial role in the identification and development of anticancer therapeutics. This study identified ustusolate E (UE) and its analog 11α-hydroxy-ustusolate E (HUE) from strain Aspergilluscalidoustus TJ403-EL05, and examined their antitumor activities and mechanisms of action. The findings demonstrate that both compounds significantly inhibited the proliferation and colony formation of AGS (human gastric cancer cells) and 786-O (human renal clear cell carcinoma cells), induced irreversible DNA damage, blocked the cell cycle at the G2/M phase, and further induced apoptosis in tumor cells. To the best of the authors' knowledge, this is the first report on the anticancer effects of UE and HUE and their underlying mechanisms. The present study suggests that HUE and UE could serve as lead compounds for the development of novel anticancer drugs.
Humans
;
Apoptosis/drug effects*
;
TOR Serine-Threonine Kinases/genetics*
;
Proto-Oncogene Proteins c-akt/genetics*
;
Cell Line, Tumor
;
Phosphatidylinositol 3-Kinases/genetics*
;
Signal Transduction/drug effects*
;
Tumor Suppressor Protein p53/genetics*
;
Cell Proliferation/drug effects*
;
Antineoplastic Agents/pharmacology*
;
Sesquiterpenes/pharmacology*
;
Aspergillus/chemistry*
2.Structurally diverse sesquiterpenoids with anti-MDR cancer activity from Penicillium roqueforti.
Shuyuan MO ; Nanjin DING ; Zhihong HUANG ; Jun YAO ; Weiguang SUN ; Jianping WANG ; Yonghui ZHANG ; Zhengxi HU
Chinese Journal of Natural Medicines (English Ed.) 2025;23(4):504-512
Five novel nor-eremophilane-type sesquiterpenoids, peniroqueforins E-H and J (1-4 and 7), two new eremophilane-type sesquiterpenoids, peniroqueforins I and K (5 and 8), and a new eudesmane-type sesquiterpenoid, peniroqueforin L (9), along with four known compounds (6 and 10-12), were isolated and characterized from fungus Penicillium roqueforti (P. roqueforti). The structures and absolute configurations of these compounds were determined through comprehensive spectroscopic analyses, electronic circular dichroism (ECD) data analyses, and single-crystal X-ray diffraction methods. The anti-multi-drug resistance (MDR) cancer activity of these compounds was evaluated using SW620/Ad300 cells. Notably, the half maximal inhibitory concentration (IC50) value of paclitaxel (PTX) combined with 1 in SW620/Ad300 cells was 50.36 nmol·L-1, which was 65-fold more potent than PTX alone (IC50 3.26 μmol·L-1). Subsequent molecular docking studies revealed an affinity between compound 1 and P-glycoprotein (P-gp), suggesting that this nor-eremophilane-type sesquiterpenoid (1) could serve as a potential lead for MDR reversal in cancer cells through P-gp inhibition.
Penicillium/chemistry*
;
Humans
;
Sesquiterpenes/isolation & purification*
;
Cell Line, Tumor
;
Molecular Structure
;
Drug Resistance, Neoplasm/drug effects*
;
Antineoplastic Agents/pharmacology*
;
Drug Resistance, Multiple/drug effects*
;
Molecular Docking Simulation
3.Changes and significance of serum pro-gastrin-releasing peptide, squamous cell carcinoma-related antigen and carbohydrateantigen 72-4 in patients with gastric cancer
Fei HU ; Kechang ZHANG ; Feng CHEN ; Zhengxi TONG ; Xiu TU
Journal of Clinical Medicine in Practice 2024;28(12):46-50
Objective To investigate the changes and clinical significance of serum pro-gastrin-releasing peptide (ProGRP), squamous cell carcinoma-related antigen (SCC), and carbohydrate antigen 72-4 (CA72-4) levels in patients with gastric cancer. Methods A total of 68 patients with gastric cancer (gastric cancer group), 37 patients with benign gastric lesions (benign gastric lesion group), and 30 healthy subjects (non-gastric disease group) were selected as the study participants. Serum ProGRP, SCC, and CA72-4 levels were compared among the three groups on admission. The relationships of serum ProGRP, SCC, and CA72-4 levels with pathological parameters were analyzed in the gastric cancer group. Patients in the gastric cancer group were followed up for 24-month after discharge. Multivariate Logistic regression analysis was used to identify the influencing factors of prognosis in gastric cancer patients. Receiver operating characteristic (ROC) curves were plotted and the area under the curve (AUC) was calculated to analyze the predictive value of serum ProGRP, SCC, and CA72-4 for death during follow-up in gastric cancer patients. Results The serum levels of ProGRP, SCC, and CA72-4 in the gastric cancer group were higher than those in the benign gastric lesion group and the non-gastric disease group, and the serum levels of ProGRP and CA72-4 in the benign gastric lesion group were higher than those in the non-gastric disease group (


Result Analysis
Print
Save
E-mail